Trials / Completed
CompletedNCT01272128
Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
A Multicenter, Prospective Non-interventional Study to Evaluate the Quality of Life in Belgian Patients With CIS or RRMS in Whom Interferon Beta-1a IM Treatment Has Been Initiated
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to assess the quality of life of intramuscular (IM) Interferon Beta-1a in participants with relapsing remitting multiple sclerosis (RRMS) or Clinically Isolated Syndrome (CIS) in a clinical practice setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon beta-1a | Interferon beta-1a will not be provided as a part of this study. Participants will receive Interferon beta-1a as prescribed by their treating physician prior to enrollment. |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2014-09-01
- Completion
- 2015-09-01
- First posted
- 2011-01-07
- Last updated
- 2015-10-20
Locations
17 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT01272128. Inclusion in this directory is not an endorsement.